Application Deadline Draws Near for 1999 Charles E. Culpeper Foundation Scholarships in Medical Science

Publication
Article
OncologyONCOLOGY Vol 12 No 6
Volume 12
Issue 6

The Charles E. Culpeper Foundation is currently accepting applications for its 1999 Scholarships in Medical Science Program, designed to support the career development of academic physicians

The Charles E. Culpeper Foundation is currently accepting applications for its 1999 Scholarships in Medical Science Program, designed to support the career development of academic physicians.

Up to four awards of $100,000 per year for 3 years will be made to United States medical schools on behalf of candidates who are US citizens or aliens who have been granted permanent US residence (proof required), have received their md degree from a US medical school in 1990 or later (except under extraordinary circumstances), and are judged worthy of support by virtue of the quality of their research proposals. All scientific research relevant to human health is eligible for consideration. No institution may nominate more than one candidate.

In selecting awardees, emphasis will be on identifying young physicians with clear potential for making substantial contributions to science as academic physicians. Since January 1988, 33 physicians have been selected as Charles E. Culpeper Foundation Medical Scholars.

The deadline for applications is August 14, 1998. Awards will be announced in January 1999, for activation on or about July 1, 1999. Application forms and instructions may be obtained on the Web at www.culpeper.org or by contacting the Charles E. Culpeper Foundation at Financial Centre, 695 East Main Street, Stanford, CT 06901-2155 (telephone: 203-975-1240; fax phone: 203-975-1847).

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
4 experts in this video
4 experts in this video
Related Content